دورية أكاديمية

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

التفاصيل البيبلوغرافية
العنوان: Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
المؤلفون: Merola, Joseph F, Landewé, Robert, McInnes, Iain B *, Mease, Philip J, Ritchlin, Christopher T, Tanaka, Yoshiya, Asahina, Akihiko, Behrens, Frank, Gladman, Dafna D, Gossec, Laure, Gottlieb, Alice B, Thaçi, Diamant, Warren, Richard B, Ink, Barbara, Assudani, Deepak, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Coates, Laura C
المصدر: In The Lancet 7-13 January 2023 401(10370):38-48
قاعدة البيانات: ScienceDirect
الوصف
تدمد:01406736
DOI:10.1016/S0140-6736(22)02303-0